Journal of Medicinal Chemistry · 2014 · 111 citations · 41 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsAntiviral AgentsAntiviral PharmacologyAntiviral TherapyEnzyme InhibitionLead DiscoveryViral HepatitisAntiviral Drug DesignAntiviral Safety AssessmentAntiviral Structure-activity RelationshipsAntiviral TherapeuticsAntiviral ToxicologyChemical Structure-activity RelationshipsPhase Iii Clinical Trials
The discovery of asunaprevir (BMS-650032, 24) is described. This tripeptidic acylsulfonamide inhibitor of the NS3/4A enzyme is currently in phase III clinical trials for the treatment of hepatitis C virus infection. The discovery of 24 was enabled by employing an isolated rabbit heart model to screen for the cardiovascular (CV) liabilities (changes to HR and SNRT) that were responsible for the discontinuation of an earlier lead from this chemical series, BMS-605339 (1), from clinical trials. The structure-activity relationships (SARs) developed with respect to CV effects established that small structural changes to the P2* subsite of the molecule had a significant impact on the CV profile of a given compound. The antiviral activity, preclincial PK profile, and toxicology studies in rat and dog supported clinical development of BMS-650032 (24).
41
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Min Gao, Richard E. Nettles, Makonen Belema et al. · Nature · 2010 · 937 citations · Full text
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
Anna S. Lok, David Gardiner, Eric Lawitz et al. · New England Journal of Medicine · 2012 · 609 citations · Full text